President, Research and Development · Revolution Medicines, Inc. (RVMD)

Steve FRCPath

A named executive officer of Revolution Medicines in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,949,607

Salary $573,333Stock awards $1,531,720

FY2023: $4,394,499

2nd of 6 named executive officers at Revolution Medicines by FY2024 total.

6 named officers on file for Revolution Medicines, FY2024

Steve FRCPath’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • RVMD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Revolution Medicines’s whole pay program stands against its peers

  • Revolution Medicines’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RVMD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Free

Get Steve FRCPath’s full pay file as a PDF — free

More than this page: up to 10 years of Steve’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Steve FRCPath compensation by year

Revolution Medicines Summary Compensation Table · all 4 fiscal years held
In US dollars, as Revolution Medicines reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023FY2024
Salary$482,333$497,500$512,575$573,333
Bonus$0$0$0$0
Stock awards$636,750$720,128$1,060,000$1,531,720
Option awards$1,486,522$1,583,971$2,522,324$3,465,953
Non-equity incentive$283,700$274,500$292,600$371,600
Pension and deferred compensation$0$0$0$0
All other$7,000$7,000$7,000$7,000
Total$2,896,305$3,083,099$4,394,499$5,949,607

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revolution Medicines, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182453, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Revolution Medicines, Inc. filed document, accession 0001193125-26-182453. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

$2.9M
$3.1M
$4.4M
$5.9M
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Revolution Medicines’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Mark GoldsmithPresident and Chief Executive Officer$10,079,491
Steve FRCPath · this pagePresident, Research and Development$5,949,607
Margaret HornChief Operating Officer$4,884,404
Jack AndersChief Financial Officer$3,292,532
Sc.D. Xiaolin WangExecutive Vice President, Development$3,054,190
Jeffrey CisliniGeneral Counsel and Secretary$2,743,217

The full Revolution Medicines compensation record

free company brief

This page is one person within Revolution Medicines's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Revolution Medicines proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revolution Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steve FRCPath's compensation dossier · One-time report. No refunds.